Your session is about to expire
← Back to Search
Neurotoxin
Botulinum toxin injections for Chronic Exertional Compartment Syndrome (Botox Trial)
Phase 2 & 3
Waitlist Available
Led By Brett Boyce, MD
Research Sponsored by 375th Medical Group, Scott Air Force Base
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
We will investigate the feasibility of a simple outpatient one time injection regimen for the treatment of Chronic Exertional Compartment Syndrome (CECS). We think botulinum toxin injections will be a potentially cost-effective, low-risk alternative to surgery in reducing pain and returning patients to full activity.
Eligible Conditions
- Chronic Exertional Compartment Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Lower Extremity Functional Index
Side effects data
From 2018 Phase 3 trial • 351 Patients • NCT020028846%
Nasopharyngitis
2%
Bronchitis
1%
Epilepsy
100%
80%
60%
40%
20%
0%
Study treatment Arm
MP Low Dose Group
MP Mid Dose Group
MP High Dose Group
OLEX (3 Injections)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Botulinum toxin injectionsExperimental Treatment1 Intervention
Botulinum toxin injections for chronic compartment syndrome
Group II: surgical fasciotomyActive Control1 Intervention
surgical fasciotomy for chronic compartment syndrome
Find a Location
Who is running the clinical trial?
375th Medical Group, Scott Air Force BaseLead Sponsor
1 Previous Clinical Trials
75 Total Patients Enrolled
Brett Boyce, MDPrincipal InvestigatorPrincipal Investigator
Share this study with friends
Copy Link
Messenger